Over many years, recombinant protein biologics developers have addressed product immunogenicity with a focus on the active pharmaceutical ingredient. Recently, immune responses to the native host cell proteins (HCP) have gained attention, as they too may have an effect on the immune response to the formulated drug, namely diminished drug safety and efficacy.

Click here to read more.